Literature DB >> 16769594

Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.

Gamal Sidra, Cathy D Williams, Nigel H Russell, Sonya Zaman, Bethan Myers, Jennifer L Byrne.   

Abstract

We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma. We found that this combination was highly effective in inducing responses in all treatment groups with an overall response rate of 83.8%. CTD was well tolerated and did not impair stem cell mobilization.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16769594

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  9 in total

1.  Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro Coy; Gordon Cook; Sylvia Feyler; Peter R E Johnson; Claudius Rudin; Mark T Drayson; Roger G Owen; Fiona M Ross; Nigel H Russell; Graham H Jackson; J Anthony Child
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

2.  Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen.

Authors:  Sung-Hoon Jung; Hyungchul Park; Jae-Sook Ahn; Deok-Hwan Yang; Mi-Young Kim; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Int J Hematol       Date:  2012-12-12       Impact factor: 2.490

Review 3.  Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Angelo Vacca
Journal:  World J Methodol       Date:  2014-06-26

Review 4.  A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Authors:  B Franken; N W C J van de Donk; J C Cloos; S Zweegman; H M Lokhorst
Journal:  Ther Adv Hematol       Date:  2016-09-13

Review 5.  Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.

Authors:  Antonio Palumbo; Carmela Palladino
Journal:  Ther Adv Drug Saf       Date:  2012-10

6.  Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Authors:  Britta Auel; Hartmut Goldschmidt; Thomas Geer; Thomas M Moehler; Uwe Platzbecker; Ralph Naumann; Igor Blau; Mathias Hänel; Wolfgang Knauf; Holger Nückel; Hans-Jürgen Salwender; Christof Scheid; Katja Weisel; Marcus Gorschlüter; Axel Glasmacher; Ingo G H Schmidt-Wolf
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-18       Impact factor: 0.900

7.  Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.

Authors:  Vânia Tietsche de Moraes Hungria; Edvan de Queiroz Crusoe; Adriana Alvarez Quero; Manuella Sampaio; Angelo Maiolino; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 8.  Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Authors:  Inger S Nijhof; Niels W C J van de Donk; Sonja Zweegman; Henk M Lokhorst
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

9.  Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.

Authors:  Shigeki Ito; Tatsuo Oyake; Kazunori Murai; Yoji Ishida
Journal:  Case Rep Hematol       Date:  2013-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.